Less Ads, More Data, More Tools Register for FREE

Pin to quick picksSynthomer Regulatory News (SYNT)

Share Price Information for Synthomer (SYNT)

Share Price is delayed by 15 minutes
Get Live Data
103.20    0.00 (0.00%)
Bid:
82.00
Ask:
0.00
Spread: 22.20 (27.073%)
Market Cap: £169.19m
SYNT Live PriceLast checked at - London Stock Exchange

Intraday Synthomer Share Chart

Q1 Trading Update

25 Apr 2019 07:00

RNS Number : 0602X
Synthomer PLC
25 April 2019
 

25th April 2019

 

Synthomer plc

Q1 Trading Update

Q1 in line with expectations; Full Year 2019 outlook unchanged

Synthomer plc ('Synthomer' or 'the Group') today issues a trading update for the quarter ended March 31st, 2019.

Group performance has been consistent with expectations set out at Synthomer's Full Year results presentation on March 4th, 2019 and our Full Year 2019 outlook remains unchanged.

Trading*

Performance Elastomers

Performance Elastomers had a solid quarter. Nitrile Butadiene Latex (Nitrile) continued to benefit from the additional 90KT of capacity introduced in Q4 2018 at our Pasir Gudang site. Good demand resulted in higher Nitrile volumes and improved unit margins relative to a strong comparative period in 2018. Styrene Butadiene Rubber market conditions remained challenging with the subdued demand seen in Q4 2018 continuing during early Q1 2019.

Functional Solutions

Functional Solutions made good progress in Q1 2019. Whilst reported volumes were lower than the strong comparative period due to the slower start to the year in Europe and the sale of 51% of our Dubai operations in July 2018, unit margins were stronger. The expansion of our Worms, Germany and Roebuck, USA dispersions facilities are on track to be commissioned in Q2 2019.

Industrial Specialities

Industrial Specialities results were in line with expectations. Compared to a strong Q1 2018, the business experienced a slower start to the year particularly in Europe but we are pleased with the improving trend during Q1, and the end of quarter exit rates.

 

2019 outlook unchanged

Overall, the Group continues to trade in line with the Board's expectations, and accordingly the view for Full Year 2019 outlook remains unchanged.

-ENDS-

* In January 2019, Synthomer introduced three new business groups: Performance Elastomers (Styrene Butadiene Rubber and Nitrile Butadiene Latex), Functional Solutions (Dispersions) and Industrial Specialities. This is how the Group intends to report on a permanent basis going forward. 

 

ENQUIRIES:

Calum MacLean, Chief Executive Officer

Stephen Bennett, Chief Financial Officer

Tim Hughes, Head of Investor Relations

Tel: + 44 1279 436211

Charles Armistead, Teneo

Tel: + 44 20 3603 5220

The Company will hold a conference call for investors and analysts at 0800 BST today:

Dial in number: 08003589473 PIN: 38068114#

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
 
END
 
 
TSTUVSVRKWASURR
Date   Source Headline
1st Jun 20262:42 pmRNSHolding(s) in Company
29th May 20263:57 pmRNSTotal Voting Rights
22nd May 20265:21 pmRNSNotice of AGM
8th May 20264:33 pmRNSAdmission to Trading
7th May 20261:51 pmRNSApplication for Admission to Trading
5th May 20264:25 pmRNSHolding(s) in Company
30th Apr 20264:40 pmRNSAnnual Financial Report
30th Apr 20263:17 pmRNSDirector/PDMR Shareholding
30th Apr 202611:25 amRNSDirector/PDMR Shareholding
30th Apr 20267:01 amRNSChange of Chief Financial Officer
30th Apr 20267:00 amRNSFinal Results
19th Mar 20267:00 amRNSTrading and refinancing update
11th Feb 20261:46 pmRNSStatement re potential refinancing
29th Jan 20267:00 amRNSTrading Statement - Winter 2026
27th Jan 20264:51 pmRNSHolding(s) in Company
26th Jan 20264:23 pmRNSHolding(s) in Company
18th Dec 20257:00 amRNSReceivables purchasing arrangement
12th Dec 20259:30 amRNSDirectorate change
12th Nov 20257:00 amRNSDirector/PDMR Shareholding
5th Nov 20251:28 pmRNSHolding(s) in Company
23rd Oct 20257:00 amRNSTrading statement - Autumn 2025
14th Oct 20257:00 amRNSAppointment of joint corporate broker
4th Sep 20255:17 pmRNSHolding(s) in Company
11th Aug 20258:00 amRNSDirector/PDMR Shareholding
6th Aug 20259:45 amRNSDirector/PDMR Shareholding
5th Aug 202511:57 amRNSDirector/PDMR Shareholding
5th Aug 202511:00 amRNSDirectorate Change
5th Aug 20257:00 amRNSInterim results
4th Jul 20257:01 amRNSDirector/PDMR Shareholding
1st Jul 20257:00 amRNSCovenant update
30th Jun 20257:00 amRNSDirectorate Changes
27th Jun 20254:21 pmRNSHolding(s) in Company
2nd Jun 20257:00 amRNSDivestment of William Blythe completed
6th May 20257:00 amRNSDivestment of William Blythe
1st May 20254:18 pmRNSResults of AGM
1st May 20257:00 amRNSTrading Statement - Spring 2025
15th Apr 20253:00 pmRNSHolding(s) in Company
28th Mar 20257:30 amRNSDirector/PDMR Shareholding
27th Mar 20257:30 amRNSDirector/PDMR Shareholding
25th Mar 20254:23 pmRNSAnnual Report and Notice of AGM
25th Mar 202511:43 amRNSDirector/PDMR Shareholding
25th Mar 202511:41 amRNSDirector/PDMR Shareholding
24th Mar 20257:30 amRNSHolding(s) in Company
17th Mar 20259:00 amRNSDirector/PDMR Shareholding
17th Mar 20259:00 amRNSDirector/PDMR Shareholding
11th Mar 20257:00 amRNSFinal Results
6th Mar 20258:32 amRNSDirector Declaration
13th Feb 20257:00 amRNSHolding(s) in Company
28th Jan 202510:30 amRNSDirector/PDMR Shareholding
28th Jan 20257:00 amRNSWinter trading statement

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.